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Abstract: The concept of the cardiovascular continuum, introduced during the early 1990s, created a holistic view of the chain of 
events connecting cardiovascular-related risk factors with the progressive development of pathological-related tissue remodelling 
and   ultimately, heart failure and death. Understanding of the tissue-specific changes, and new technologies developed over the last 
25–30 years, enabled tissue remodelling events to be monitored in vivo and cardiovascular disease to be diagnosed more reliably than 
before. The tangible product of this evolution was the introduction of a number of biochemical markers such as troponin I and T, which 
are now commonly used in clinics to measure myocardial damage. However, biomarkers that can detect specific earlier stages of the 
cardiovascular continuum have yet to be generated and utilised. The majority of the existing markers are useful only in the end stages of 
the disease where few successful intervention options exist. Since a large number of patients experience a transient underlying develop-
ing pathology long before the signs or symptoms of cardiovascular disease become apparent, the requirement for new markers that can 
describe the early tissue-specific, matrix remodelling process which ultimately leads to disease is evident. This review highlights the 
importance of relating cardiac biochemical markers with specific time points along the cardiovascular continuum, especially during the 
early transient phase of pathology progression where none of the existing markers aid diagnosis.
Keywords: biomarkers, cardiovascular disease, extracellular matrix remodeling, ECMr, diagnostic markers, cardiovascular continuum, 
biomarker continuum, cardiac matrikinevassiliadis et al
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Cardiovascular Continuum (CVC)  
and Biomarkers
The  evidence-based  concept  of  a  cardiovascular 
continuum (CVC) introduced in 1991 by Dzau and 
Braunwald  ingeniously  described  the  vast  number 
of different and diverse tissue remodelling processes 
that gradually lead to cardiovascular-related pathol-
ogy, heart failure and death. Further validation and 
expansion of the CVC model was performed through 
pathophysiology and clinical trial evidence1,2 which 
highlighted the impact of risk factors related to car-
diovascular disease (CVD), such as cigarette smoking 
and diabetes, in the initiation of the CVC vicious cir-
cle which was also extended to include other affected 
organs such as the brain and the kidney. A key remark 
by Dzau et al in recent CVC validation work2 stresses 
the value of biomarkers for risk assessment, early diag-
nosis and prognosis while emphasising that markers 
that may also act as mediators of   disease.   Undoubtedly, 
a biomarker or a panel of markers which could facili-
tate stratification of patients in the appropriate CVC 
segment could prove invaluable in a clinical setting, 
as it would allow early intervention at the beginning 
of  the  CVC  where  prevention  may  be  possible.3–5 
However,  existing  biomarkers    cannot  fully  realize 
this goal as only a handful of these, mainly   troponin, 
have been found to be cardiac specific and even then, 
are only useful in detecting myocardial damage in 
the late stages of CVD, in what has recently been 
described as the vascular aging   continuum (VAC).6 
The vast majority of other biomarkers seem to be up- 
or down-regulated in non CVD-related   pathologies. 
At this time, the selection of biomarkers that can reli-
ably facilitate prognosis during the early stages of 
CVC is limited (Fig. 1). An overview of frequently 
used CVD biomarkers is presented in this paper to 
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Figure 1. existing biomarkers are valuable diagnostic and monitoring tools mainly for the end stages of cardiovascular disease.
Notes: There is currently a lack of biomarkers that can reliably describe the transient, underlying abnormal extracellular matrix remodelling (ecMr) which 
ultimately leads to cardiovascular-related pathology. The illustration of atherosclerosis progression and the lack of early biomarkers of atheromatic formation is 
indicative of this unmet need. The timeline of atheromatic formation is suggestive of the large extent of matrix remodelling which takes place over decades and 
remains unmonitored for the large part. Accurate monitoring of early cardiac ecMr could prompt early intervention and prevention of disease progression.Novel biomarkers and the cardiovascular continuum
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underline some of the strengths and weaknesses that 
these have, and propose an approach for future, novel 
biomarker development.
Clinically Relevant Cardiac Markers
creatinine kinase (cK) and cK-MB
Creatinine kinase MB is an enzyme present   primarily 
in  cardiac  muscle.  The  MB  is  one  of  the  three 
CK  isoenzymes  the  other  being  the  MM  and  BB. 
CK-MB is released rapidly after myocardial injury.7 
During an onset of acute myocardial infarction (AMI), 
CK-MB rises to twice the normal levels within 6 hours 
and  peaks  within  12–24  hours.8–10  Serial  CK-MB 
mass measurements have a nearly 90% sensitivity of 
AMI three hours after a patient is first assessed in a 
hospital  emergency  department,  which  equates  to 
approximately 6 hours after symptom onset, but these 
measurements are only 36%–48% sensitive when used 
at, or shortly after, presentation.9,11 CK-MB plays an 
important role in defining the infarct size, expansion 
and risk of re-infarction. If a cTn is not available, the 
CK-MB is considered the best alternative marker of 
AMI. Decades ago, elevated serum levels of CK-MB, 
the cardiac-specific isoform of CK, were also used as 
biomarkers for the diagnosis of myocardial necrosis. 
This measure satisfied one component of the diagnos-
tic criteria for MI, as proposed by the World Health 
Organization, and its use was later extended to moni-
tor trends and determinants in a cardiovascular disease 
study.12 Even though the CK-MB has been proven a 
relatively  sensitive  measure  of  myocardial  necrosis 
and AMI, this enzyme is not exclusively specific to 
myocardial damage, as elevated levels in several con-
ditions following acute or chronic muscle injury and 
in patients undergoing surgical procedures, have been 
found.13 Furthermore, CK is present in the intestine, dia-
phragm, uterus and prostate, and injury to these organs 
would result in release of CK-MB and thus impair the 
specificity of CK-MB serum measurements. In order 
increase the specificity of CK-MB measurements and 
thereby distinguish the “true   positive” serum eleva-
tions secondary to myocardial injury from the “false 
positive”  elevations  due  to  other  tissue  injury,  the 
measurement of CK-MB as a percentage of total CK 
has been used. There is no clear consensus on whether 
absolute CK-MB or the CK-MB relative index is the 
preferred test for patients with potential acute coro-
nary syndromes, but the World Health Organization 
international  diagnostic  criteria,  and  several  others, 
recommend use of absolute CK-MB.14
Myoglobin
Myoglobin  is  a  relatively  small,  17.8  kDa,  heme 
protein that is abundant in the cytoplasm of cardiac 
and skeletal muscle cells. The main function of myo-
globin is to transport oxygen within muscle cells, and 
it constitutes approximately 2% of muscle protein in 
both skeletal and cardiac muscles.
The  tissue/plasma  ratio  of  myoglobin  is  very 
high, and combined with its small size, myoglobin is 
  rapidly released into the circulation upon tissue necro-
sis and injury. Of the biomarkers routinely collected 
from  patients  suspected  or  diagnosed  with  CVD, 
myoglobin is generally accepted as one of the   earliest 
to  appear  during  the  development  of  the  disease. 
Elevated  levels  following  an  AMI  appear  in  the 
  circulation after 0.5–2 hours. Since myoglobin is only 
released as a result of tissue necrosis, it is a poor bio-
marker of acute cardiac ischemia.   Furthermore, myo-
cardial and skeletal muscle myoglobins share 100% 
homology, thus making this marker tissue unspecific. 
Myoglobin  is  cleared  by  kidneys,  and  it  has  been 
reported  that  patients  suffering  from  renal  insuffi-
ciency have increased plasma levels of   myoglobin, 
and thus readings may be falsely high. There is dif-
ference  of  opinion  as  to  whether  myoglobin  is  a 
useful biomarker in the evaluation of patients with 
suspected acute coronary syndromes. As assays for 
measurements of cardiac-specific biomarkers such as 
cTnI and cTnT have become available, the value of 
myoglobin as a cardiac biomarker has decreased.15 
Current guidelines recommend myoglobin measure-
ments only in patients presenting within 6 hours of 
chest-pain onset.16 Recent studies have demonstrated 
that,  among  patients  with  ST-elevation  myocardial 
infarction  (MI),  those  with  raised  myoglobin  lev-
els before the initiation of fibrinolytic therapy are at 
high risk for death and heart failure.17 For patients 
presenting to the emergency room with chest pain 
in  the  absence  of  ST-elevation,  the  addition  of 
  myoglobin to biomarker panels that include CK-MB 
and cTnI or cTnT improves sensitivity for the detec-
tion of MI, particularly in patients presenting early 
after   symptom onset.8,9,11,15,18,19 Beyond the diagnosis 
of MI, there are discrepancies as to whether myo-
globin is useful for risk-stratification in patients with vassiliadis et al
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non–ST-elevation acute coronary syndromes (ACS). 
One recent study has suggested that myoglobin pro-
vides incremental prognostic information to CK-MB 
and troponin,9 but several others have not reached the 
same conclusion.8,18,19
Lipoprotein A
Lipoprotein (A) is a low-density lipoprotein (LDL) 
particle  with  an  apolipoptotein A  (apoA)  attached. 
Apo(A)  is  linked  to  LDL  by  a  disulfide  bond.20 
This structure has significant homology to plasminogen, 
and the enhanced coronary heart disease (CHD) risk 
associated with Lp(a) is reportedly due to inhibiting 
the effects of this lipoprotein particle on plasminogen 
activation, enhancing the risk of thrombosis. Lp(a) 
may also increase atherogenicity of LDL.21,22 Many 
observational trials support the association of Lp(a) 
with enhanced cardiovascular risk.23 In general, it has 
been postulated that every 30 mg/dL increase in Lp(a) 
doubles the risk of CHD. Therapeutic modification of 
Lp(a) is controversial. Only estrogen and   niacin have 
been showed to moderately lower Lp(a).24
Brain natriuretic peptide (BNP)
Measurement  of  plasma  brain  natriuretic  peptide 
(BNP)  concentration  is  a  very  efficient  and  cost-
  effective  mass  screening  technique  for  identifying 
patients with various cardiac abnormalities, regard-
less of aetiology.25 BNP is a 32-amino acid polypep-
tide cardiac neuro-hormone secreted from membrane 
granules  in  the  cardiac  ventricles,  particularly  the 
left  ventricle,  as  a  response  to  ventricular  volume 
expansion  and  pressure  overload.25,26  Atrial  natri-
uretic peptide (ANP) and B-type natriuretic peptide 
(B-NP) are of myocardial cell origin, while C-type 
natriuretic peptide (CNP) is of endothelial origin.25 
BNP was originally named brain natriuretic peptide, 
and it was first detected in porcine brain.27,28 BNP lev-
els have been found elevated in patients with   various 
clinical  conditions  such  as  heart  failure,  MI,  left 
ventricular  hypertrophy,  cardiac  inflammation,  pri-
mary pulmonary hypertension, renal failure, ascetic 
cirrhosis and is associated with advanced age.29 The 
levels correlate with severity of symptoms and with 
prognosis, and so it helps to detect the presence of 
heart    failure,  determine  its  severity,  and  estimate 
  prognosis.  BNP  has  the  potential  to  considerably 
improve the management of patients with congestive 
heart  failure  (CHF)  and  may  become  a  routinely 
assessed serum parameter in clinical medicine. BNP 
is considerably less costly than other tests for CHD, 
and due to its cost-effectiveness is highly desirable 
in developing countries.   Originally, the US Food and 
Drug Administration (FDA) approved the use of BNP 
or NT-proBNP (amino terminal pro-brain natriuretic 
peptide) to assist in differentiating a cardiac cause 
(such as congestive heart failure) from a non-cardiac 
origin (such as chronic obstructive pulmonary disease) 
for dyspnea. Recently, NT-proBNP was approved by 
the FDA for use in assessing the prognosis of patients 
with congestive heart failure and acute coronary syn-
drome, while the BNP assay is also approved for risk 
stratification in acute coronary syndrome.30
Troponins I and T
The troponin protein complex consists of 3 subunits, 
the C (TnC) subunit which is the calcium binding 
component, the I (TnI) which maintains the struc-
tural position of the troponin-tropomyosin complex, 
and the T (TnT) which is the tropomyosin binding 
subunit. All are located on the thin filament of both 
skeletal and myocardial myocytes, the latter playing 
an integral role in the Frank-Starling mechanism of 
the heart.31,32 Interestingly, both TnT and TnI sub-
units have distinct isoforms for each muscle type, 
hence there is a specific cardiac isoform.33 Cardiac 
  troponins T and I (cTnT and cTnI) are now recognized 
as the most tissue-specific biomarkers related to car-
diac damage and have been included as a diagnostic 
criterion for several cardiac-related pathologies.34–39 
This  success  is  closely  related  to  the  troponins’ 
unique position and function in the cardiomyocyte 
and the ability to generate specific monoclonal anti-
bodies against both cTnT and cTnI which are precise 
tissue-specific biomarkers of myocardial injury that 
are not detected in healthy individuals.31 Due to the 
integral role of troponins in myocardial   contraction 
and  their  success  as  cardiac-specific  markers,  the 
question  has  risen  as  to  whether  troponin-related 
proteolysis is somehow also implicated in the devel-
opment of cardiac damage that leads to heart fail-
ure, through a gradual procedure which eventually 
leads to decreased diastolic and systolic function.34 
The notion that proteolysis is present early in cardiac 
disease and can facilitate progress to cardiac dam-
age through troponin degradation has not been yet Novel biomarkers and the cardiovascular continuum
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broadly utilised for the development of proteolytic 
fragments as cardiac-specific markers.
Osteopontin
Osteopontin (OPN) is a matricellular glycoprotein/
cytokine that has been recently found to be a promis-
ing prognostic biomarker for patients with heart fail-
ure, ischemic heart disease and cardiac   remodelling 
in both clinical and pre-clinical settings.40–44  Even 
though its expression by macrophages during myo-
cardial necrosis has been reported since 199445 its 
precise function is not fully understood. OPN has 
previously been described as a regulator of inflamma-
tion and bio-mineralisation via macrophage interac-
tion while also associated with bone remodelling.46–48 
OPN has been characterised as an independent pre-
dictor of death within 4 years for patients with heart 
failure  and  was  found  highly  elevated  in  patients 
with left ventricular dysfunction.40 However, OPN 
is  expressed  in  many  tissues  and  has  also  been 
described as a marker in non-CVD related patholo-
gies which include cancer, myeloma, multiple sclero-
sis, bone destruction, angiogenesis, Graves’ disease 
and  pulmonary  hypertension.48–54  This  inherently 
impedes the direct association of OPN up-regulation 
with the early phase of any of its related pathologies, 
particularly early CVC, prior to the development of 
other clinical symptoms that can facilitate reliable 
diagnosis.
c-reactive protein (crP)
C-reative protein (CRP) is a non-specific acute-phase 
reactant protein produced in the liver. It is associated 
with a variety of diverse functions related to immune 
reactivity  including  complement  activation,  innate 
immunity and phagocyte stimulation.55 Even though 
its usefulness was initially greeted with scepticism 
due to the fact that it has been previously used as an 
non-specific inflammatory marker,56 it has since been 
widely used as an acute inflammation marker. It has 
been found to be a reliable marker for a variety of 
CVD-related pathologies which include atheromatic 
plaque vulnerability, atherosclerosis, coronary artery 
disease, coronary vasospasm, left ventricular dysfunc-
tion, angina pectoris and myocardial infarction.57–61 
CRP levels have been found to be related to levels 
of cardiac enzymes and troponin I,61 while in some 
cases it was found to be a better marker of CVD than 
troponin T.62 CRP has been found to have a role in 
myocardial and cerebral infarct growth and has been 
consequently targeted by inhibitors to induce a car-
dio-protective effect.63 However this application has 
yet to be fully realised.64 Its reliability has several 
limitations as human CRP levels greatly vary, depend-
ing on ethnicity, gender, and genetics, and it has also 
been  associated  with  obesity  and  weight  loss.64,65 
In  addition,  it  has  been  described  as  an    indicator/
marker for non-cardiac related pathologies such as 
anastomotic leakage, systemic lupus erythematosus 
(SLE), and dementia.66–68
recent advances in identifying clinical 
markers with promising early prognostic 
and diagnostic capacity
A number of additional novel clinical markers have 
also  been  studied  recently.  Some  of  these  show 
  promising results as early prognostic and diagnostic 
markers, as outlined below, although their ultimate 
utility remains to be tested in large clinical settings.
During  the  last  10  years,  asymmetric  dimethy-
larginine  (ADMA)  has  received  much  attention  as 
a promising cardiovascular biomarker. ADMA is an 
endogenous competitive inhibitor of nitric oxide syn-
thase although it can also cause   vasoconstriction.69 
It has been found to be increased in a number of 
cardiovascular  events  that  include  atherosclerosis, 
hypertension,  coronary  artery  disease  and  chronic 
heart failure, and even on its own, is believed to be a 
novel cardiovascular risk factor.69–72 ADMA has also 
been associated with inflammation and increased risk 
of death in cardiovascular related events.73
Myeloperoxidase  (MPO)  is  another  recently 
described  biomarker  that  has  been  found  to  be  rel-
evant for heart failure, acute coronary syndrome and, 
recently, atherosclerosis.74,75 MPO is an enzyme which 
among other molecules can produce hypochlorite and 
has been shown to be released early in the inflamma-
tory process, while it has been linked to both inflamma-
tion and oxidative stress.75,76 MPO has been found to be 
related to CVD due to its involvement in LDL and HDL 
oxidation which is closely related to plaque formation 
in arterial walls through increased cholesterol aggrega-
tion.75 MPO has shown some promising early results in 
clinical settings, being able to demonstrate a diagnos-
tic value of CVD even in individuals showing negative 
results for troponin T. However, a key characteristic of vassiliadis et al
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MPO utilisation is that its elevation may not be directly 
related to cardiac or vascular tissue remodelling and 
may be attributed to underlying inflammatory processes 
which ultimately lead to organ failure.77
F2 isoprostanes are a family of prostaglandin com-
pounds derived from arachidonic acid   peroxidation 
which have recently shown promising potential as 
in vivo markers of oxidant injury in cardiovascular 
pathologies  such  as  atherosclerosis,  hypertension 
and, recently, ACS.78–80 Even though increased levels 
of this marker have been found in non-cardiovascular 
related  pathologies  such  as  Alzheimer’s  disease, 
  pulmonary disorders and renal failure, its presence has 
been strongly linked with well-known cardiovascular 
risk factors.78,81,82 However, and despite these promis-
ing results, use of F2 isoprostanes have not been used 
on a large scale. Relevant literature in large cohorts is 
limited, which restricts evaluation of its potential.
Cardiac Extracellular Matrix 
Components and Opportunities  
for Biomarker Development
cardiac extracellular matrix
The cardiac extracellular matrix (CECM) is a vibrant 
three-dimensional entity which offers structural sup-
port to which cells adhere and migrate. It consists pri-
marily of collagen, mainly type I but also III, IV, V, VI, 
glycoproteins, proteoglycans as well as diverse cell 
types  such  as  fibroblasts  and  endothelial  cells.83 
  Recognition of the constantly active dynamics of the 
CECM attracted additional attention to the possibil-
ity that its close monitoring could enhance our under-
standing of the underlying mechanisms occurring in 
the transition from physiology to pathology.84
CECM  modifications  during  the  natural  ECM 
remodelling process increase with age and are part 
of  a  physiologic  process,  particularly  because  the 
CECM  activates  cardiac  fibroblasts.85,86  However, 
unbalanced cardiac extracellular matrix remodelling 
(CECMR) can result in cardiovascular-related pathol-
ogy through a mast cell-driven process and ultimately 
in heart failure.87,88
The collagenous cardiac CECM has been shown to 
have higher turnover rates than other tissues, possibly 
due to its contribution to diastolic stiffness.89,90 The 
practical outcome of this observation was the intro-
duction and utilisation of CECM-related biomarkers 
such as procollagen types I and III (PINP, PICP, and 
PIIINP) that could monitor CECMR91 and its effects 
on diastolic dysfunction, pumping capacity and ven-
tricular volume. An additional key property of cardiac 
CECM constituents is their ability to participate in 
inflammatory pathways that ultimately affect cardiac 
repair and pathogenesis.92 Due to these exceptional 
properties as active participants of cardiac and vas-
cular remodelling, the use of CECM   constituents as 
promising non-invasive early indicators of   underlying 
developing pathology and inadequate tissue adapta-
tion has been proposed.91,93–96
cardiac matrix metalloproteinases 
(MMPs)
MMPs are a family of proteases that together with other 
proteases, such as cathepsins and elastases, play a key 
regulatory role in tissue remodelling in both physi-
ology and in a number of pathologies which include 
cancer,  fibrosis  and  CVD.97,98  Under  normal  physi-
ologic conditions, there is a balance between MMPs 
that degrade CECM components and   tissue inhibitors 
of  metalloproteinases  (TIMPs).99,100    However,  dur-
ing developing pathology, events such as decreased 
TIMP expression and activation of mast cells through 
chronic  stimuli  or  increased  stress,  can  induce 
increased MMP activation which in turn drives abnor-
mal CECMR, eventually leading to cardiac and vas-
cular disease and ultimately death.88,101 MMP activity 
has  been  implicated  in  a  large  number  of  diverse 
cardiac and vascular pathologies which include car-
diomyopathies, atherosclerosis, aneurism, myocardi-
tis, hypertension and viral heart disease.88,97,100,102–105 
MMP effects and activity are closely related to the 
availability of substrates, some of which have been 
found to be specific for some MMPs.86 An example 
of such specificity is MMP-8, -3 and -13 which have 
been  described  as  specific  for  fibrillar  collagens; 
MMP-7  against  collagens  I,  III  and  proteoglycans; 
while  MMP-2  and  -9  were  found  to  preferentially 
cleave  proteoglycans  in  myocardial  tissue.97,102 
  Analogous substrate-MMP specificities and interac-
tions have been reported in the ECM of both cardiac 
and  vascular  components,  further  highlighting  the 
importance  of  these  interactions  in  ECMR  during 
physiology and pathology.106–111 The tangible product 
of this recognition was MMP utilisation as CECMR Novel biomarkers and the cardiovascular continuum
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specific markers with promising results.105,112 MMPs 
are  also  actively  employed  in  non-cardiovascular 
related   tissues and organs which include liver, skin, 
and lung. This presents the practical problem of how 
to pin-point the   precise tissue source of the substrate-
MMP biomarker. Biomarkers that rely on MMPs and 
their action on specific substrates to form tissue-specific 
neoepitopes  have  been  successfully  employed  for 
ECMR- related pathologies other than cardiovascular. 
The utilisation of such technologies should be further 
investigated for cardiovascular pathologies.98,113–119
MMPs and ecM remodelling  
in atherosclerosis
In  most  cases  the  underlying  cause  of  CVD  is 
  atherosclerosis.  Vulnerable  atherosclerotic  plaques 
are  characterized  by  their  propensity  to  rupture, 
exposing  thrombogenic  material  to  the  circulation 
and consequently initiating the formation of luminal 
thrombi and ischemia. One of the key determinants of 
lesion stability is the composition and integrity of the 
plaque ECM. The quantity and quality of the ECM is 
of paramount importance in defining plaque stability. 
For instance, stable ECM-rich plaques which remain 
generally  asymptomatic  are  characterized  by  their 
dense ECM, composed primarily of fibrillar and non-
fibrillar collagens and proteoglycans. On the other 
hand, vulnerable or unstable plaques have a thin and 
disrupted fibrous cap and the collagen content in the 
ECM is clearly reduced.108 The proteolytic activity 
of MMPs is a key regulator of ECM integrity in ath-
erosclerosis.120 Several studies have shown increased 
expression and activity of MMPs, including MMP-1, 
-2, -3 and -9, in vulnerable areas of atherosclerotic 
plaques.121,122 While MMPs could collectively target 
many different ECM components, most studies have 
focused on the collagenolysis, especially of type I 
  collagen, taking place in lesions. In one of the key 
studies,  the  proteolytic  activity  was  attributed  to 
MMP-1  and  -13.123  Another  proteinase  which  has 
received substantial attention is MMP-9.   Synthesis of 
active MMP-9 by macrophages and smooth muscle 
cells was demonstrated in human coronary atherec-
tomy specimens taken from patients with unstable 
angina but was not found in stable patients.124 MMP-9 
is one of the few extracellular proteins with biomarker 
potential in CVD.125 While collagen degradation has 
been studied in detail, little is known of the proteolytic 
processing  of  other  ECM  components,  especially 
glycoproteins  and  proteoglycans.  One  of  the  main 
non-collagen components of vessels with important 
structural and regulatory functions is the large aggre-
gating proteoglycan versican. Halpert et al showed 
that versican could be a substrate for MMP-7 and -12 
at  sites  of  plaque  rupture.126 Although  MMP-12  is 
a protease with general substrate   specificity and is 
highly expressed by activated macrophages, its role 
in atherosclerosis is not well understood.127   However, 
it is known to play a key role in the pathological 
development  of  abdominal  aortic  aneurysms,  not 
only because it cleaves elastin and type I collagen but 
because it targets various ECM glycoproteins, includ-
ing collagen XII, tenascin, fibronectin, thrombospon-
dins and periostin.106 Proteolysis of the ECM not only 
compromises its structural properties, but its degrada-
tion products have been recently shown to activate 
pro-inflammatory  signalling  via  toll-like  receptors 
(TLRs). Hyaluronic acid degradation products (that 
is, tetra- and hexa-saccharides) have the ability to act 
as endogenous TLR-2 and -4 ligands in a variety of 
cell  types,  including  macrophages  and    endothelial 
cells.128  Similarly,  the  fibronectin  splice  variant 
extra-type III domain A (EDA), has been shown to 
activate  T-cells  and  induce  MMP-9  expression  in 
human monocytes by activating TLR-4.129 The role 
of EDA fragments in CVD was recently highlighted 
by Arslan  and    colleagues.130  Moreover,  Kim  et  al 
recently  showed  that  versican  fragments  activate 
TLR-2131 and Babelova et al described a proinflam-
matory effect of biglycan via TLR-2 and -4.132 Given 
the well-documented importance of TLR-2 and -4 in 
human  atherosclerosis133  and  the  extensive  remod-
elling of the ECM in CVD, the connection between 
MMP activity and the generation of bioactive, pro-
inflammatory fragments from ECM proteins needs to 
be further investigated.
cecM matrikines
As seen in the previous sections, CECM and its con-
stant interaction with proteases constitutes a complex 
and active entity in both physiology and pathology. 
The accumulated information on the continuous inter-
action between proteases and ECM gave birth to the 
conception of matrikines. The term was used to describe vassiliadis et al
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peptides formed by protease-driven ECM proteolysis 
that were able to regulate cell activities via interaction 
cell surface receptors-.134 The finding that matrikines 
can regulate both ECM   synthesis and remodelling as 
well as MMP production and activation is indicative of 
the strong influence they may have in physiology and 
in transition processes that ultimately lead to patholo-
gy.135 A number of proteins including elastin, various 
collagen types,   glycoproteins and laminin134,136 have 
been recently described as ECM matrikine sources 
and mainly indicate the presence of tumours. How-
ever, the fact that most of these proteins exist in a large 
variety of tissues increases the possibility that these 
may be implicated in other pathologies. Angiogen-
esis is a prime example of such an occurrence, since 
it takes place in a variety of diverse processes such 
as arthritis, wound healing, tumour growth, and car-
diovascular-related events such as atherosclerosis and 
post-ischemic vascularisation of the myocardium.137 
Even though cardiovascular specific matrikines have 
not  yet  been  described  in  detail,  cardiovascular-re-
lated proteins such as elastin and their remodelling has 
been previously associated with angiogenesis, related 
inflammatory infiltrate and severity of atherosclerosis 
and  aneurism  progression.137–139  The  possibility  of 
  cardiac-specific matrikines being implicated in cardio-
vascular   pathology-related events, whether directly or 
indirectly should be further studied. The large num-
ber  of  potential  combinations  of  peptide  cleavages 
between  cardiac-specific  ECM  protein  constituents 
and proteases could result in a great number of matrik-
ines that even though locally generated could have an 
effect on both adjacent and distant cells and tissues.
The above is a significant task., The example of 
successful utilisation of neoepitopes as biomarkers 
for a number of different pathologies is indicative of 
potential benefits of such approach98,113–116,119 in this 
case. The question arises whether certain neoepitopes 
could also act as matrikines. Since both neoepitopes 
and matrikines are generated by proteolytic action 
of proteases on ECM, this possibility may exist and 
should be further assessed.
Discussion-Cardiovascular Continuum 
and Novel Cardiac Biomarkers
The discovery of novel and tissue-specific cardiac 
biomarkers that can reliably assess pathologic condi-
tions is important for early detection and prevention 
of cardiac damage. The existing panel of markers 
with  the  important  addition  of  troponin  markers 
constitutes  a  reliable  set  of  tools.  However,  other 
markers  are  needed  to  describe  underlying  and 
developing pathology in the early, transient stages 
of CVC which elude existing late-stage diagnostic 
and prognostic means. The technology of   combining 
  protease-driven  ECMR  and  the  resulting  peptide 
fragment “fingerprints” as markers of ECM moni-
toring  has  provided  a  number  of  reliable  markers 
for  ECMR  pathologies98,113,115,116,119  which  recently 
included  cardiac-specific  events  such  as  arterial 
remodelling.140 The long timeline that separates risk 
factors  which  transiently  develop  to  CVD-related 
pathology and ultimately cardiovascular death in the 
CVC include, as already described above, a large 
number of protease and protein interactions as key 
participants in ECMR. These protease and protein 
interactions could provide excellent markers of tis-
sue remodelling closely reflecting different stages in 
the disease continuum (Figs. 2 and 3).
The possibility that such CECMR fragments may 
also  act  as  matrikines  which  affect  cell  activities 
via cell surface receptors further adds to the impor-
tance of accurate measurements of such   fragments. 
  Measuring these fragments could potentially reflect 
protease production, cell apoptosis, proliferation and 
migration.  Cardiac-specific  proteins  and  a  detailed 
description  of  the  precise  proteolytic  activity  of 
proteases  on  these  proteins  in  vivo  could  provide 
a  prime  resource  of  such  biomarker  development. 
The successful use of troponins suggests that other 
  cardiac-specific  proteins  such  as  titin,  which  also 
have cardiac specific regions, could be identified as 
useful matrikines. During the identification of bio-
markers, it would be helpful to investigate their tissue 
and disease stage-specific post-translational modifi-
cations (PTMs), which may add supplementary infor-
mation  for  detailed  disease-staging. We  previously 
discussed  that  since  PTMs  are  modifications  that 
take place following protein translation and are not 
DNA-coded, their presence may be related to tissue 
physiology or pathology either as a cause or a conse-
quence and could therefore be included in the design 
of tissue-specific biomarkers.141 Identification of spe-
cific PTMs and their association with specific time 
points  of  disease  progression  could  add  important 
information to the proposed biomarker continuum, Novel biomarkers and the cardiovascular continuum
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Figure 2. Proteolytic activity by proteases such as matrix metalloproteinases (MMPs) is an important regulator of extracellular matrix (ecM) integrity in 
  atherosclerosis, which is the central pathological feature of cvD. Interaction of different proteases combined with an altered ecM phenotype during atheroma 
formation and disease progression could result in a distinct neo epitope formation which could be used to monitor abnormal cardiac ecM remodelling and stage 
the disease. These neoepitopes are informative of protease activity, potential post- translational modifications of proteins, and tissue remodelling (A).   combining 
such biomarkers with a specific relationship to the location of atheroma formation could enable close monitoring of atherosclerosis progression (B).
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Figure 3. A proposed illustration of a biomarker continuum, which could facilitate disease staging by utilisation of specific biomarkers that correspond to 
precise extracellular matrix remodelling (ecMr) events.
Notes: A serum measurement of biomarkers would provide information on all atherosclerotic plaques and the underlying activity of both proteases and 
ECMR. For a specific clinical phenotype, the marker or combination of markers may provide more information on the specific number of plaques and 
degree of ecMr and protease activity, and thus of disease-staging.vassiliadis et al
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thus creating a detailed disease staging network of 
biomarkers  that  are  informative  of  underlying  and 
developing  pathology.  Introduction  and  utilisation 
of well-described biomarkers that are closely related 
to  CVD-staging  could  facilitate  their  classification 
to specific pathology-linked time points in a simi-
lar way as the BIPED criteria did for biomarkers in 
osteoarthritis142.
We  believe  that  the  main  challenge  of  future 
  biomarker translational research lies in the detailed 
mapping of tissue-specific relevant protein substrates, 
identification of tissue-specific acting proteases, and 
tissue-specific PTMs. These could be combined in 
biomarker  development  and  concurrently  increase 
our understanding of CVD initiation and   progression. 
Biomarkers relating to the early transient stages of 
CVD could enable early intervention and modifica-
tion of the path of such a commonplace, but often 
fatal, disease.
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